Novartis (NOVN) PT Set at CHF 84 by JPMorgan Chase & Co.
Several other research firms have also issued reports on NOVN. UBS Group set a CHF 78 target price on Novartis and gave the stock a neutral rating in a report on Monday, October 23rd. Morgan Stanley set a CHF 88 target price on Novartis and gave the stock a buy rating in a report on Friday, October 20th. Deutsche Bank set a CHF 83.50 target price on Novartis and gave the stock a neutral rating in a report on Wednesday, October 4th. S&P Global set a CHF 87 target price on Novartis and gave the stock a neutral rating in a report on Tuesday, October 24th. Finally, set a CHF 90 target price on Novartis and gave the stock a buy rating in a report on Monday, October 30th. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and seven have issued a buy rating to the stock. Novartis currently has an average rating of Hold and a consensus target price of CHF 86.97.
Shares of Novartis (VTX:NOVN) opened at CHF 83.88 on Wednesday. The stock has a market capitalization of $218,960.00 and a price-to-earnings ratio of 30.61. Novartis has a 1-year low of CHF 69.50 and a 1-year high of CHF 85.40.
Novartis Company Profile
Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with Analyst Ratings Network's FREE daily email newsletter.